CP1
Director Trades
| Date | Director | Value |
|---|
Company News
CannPal closer to commercialisation of DermaCann after it reduces canine dermatitis in study
CannPal Animal Therapeutics (ASX: CP1) is a step closer to commercialisation after its oral hemp-based CBD nutraceutical DermaCann was shown to “substantially” reduce atopic dermatitis in dogs during a recent clinical study. The company has developed DermaCann to promote skin health and immune function in canines. During a clinical trial over eight weeks, two similar […]
CannPal secures commercial rights to CSIRO’s MicroMAX technology
Following an 18 month review, CannPal (ASX: CP1) has secured exclusive rights to commercialise the Commonwealth Scientific and Industrial Research Organisation’s (CSIRO) patented MicroMAX platform for use in its hemp and cannabis-based animal health products. CannPal now has exclusive global rights to commercialise MicroMAX, which is designed to encapsulate microscopic droplets of oil in a […]
CannPal Animal Therapeutics to conduct veterinary research alongside the University of Melbourne
CannPal Animal Therapeutics (ASX: CP1) is looking to develop and broaden its research pipeline after announcing that it has signed a memorandum of understanding (MoU) with the University of Melbourne. The deal could pave the way for the animal health company to manufacture cannabidiol-based drugs that combat epilepsy in dogs, and thereby create an entirely […]
CannPal and CSIRO to advance cannabinoid medicines for pets
Animal health company CannPal Animal Therapeutics (ASX: CP1) has entered into a research agreement with the Commonwealth Scientific and Industrial Research Organisation (CSIRO) under the CSIRO’s Kick-Start initiative. CSIRO’s Kick-Start program was launched in April 2017, providing innovative Australian start-ups with funding support and access to CSIRO’s research expertise and facilities. The program offers eligible […]
CannPal secures Australian cannabis import licence to bring in formulations for research
CannPal Animal Therapeutics (ASX: CP1) has secured its import licence from the Australian Government’s Office of Drug Control, which will allow it to bring cannabis formulations into the country for research on its CPAT-01 drug. The cannabis formulations will be imported under an existing memorandum of understanding with Canada-based Aphria Inc (TSX: APH), which will supply […]
Debutant ‘pot stock’ CannPal gains NSW Govt approval for cannabis-based trials in dogs
The New South Wales Department of Health has approved CannPal Animal Therapeutics’ (ASX: CP1) application to possess and supply cannabidiol and tetrahydrocannabinol to use in its upcoming clinical trials which aim to develop its CPAT-01 drug for treating pain in dogs. Debuting on the ASX less than two weeks ago, the animal focussed health company […]
Company Videos
No videos found.